Trial Profile
An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2019
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 29 May 2017 Status changed from active, no longer recruiting to completed.
- 21 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 10 Feb 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.